Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2023-03-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事提名人声明（一）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board of directors nominating an individual as an independent director candidate. It includes detailed declarations about the nominee's qualifications, compliance with relevant laws and regulations, and independence criteria. There is no financial data, no report of financial performance, no voting results, no meeting materials, and no mention of any report publication. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4480 characters, which is consistent with a detailed nomination statement rather than a brief announcement or report publication.
2023-03-30 Chinese
关于董事、监事、高级管理人员2022年薪酬的确定及2023年薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement regarding the determination of remuneration for the company's directors, supervisors, and senior management for the year 2022 and the remuneration plan for 2023. It includes detailed salary figures and the remuneration policy but does not contain financial statements or performance data typical of annual or interim reports. The content focuses on compensation information for executives and board members, which aligns with the definition of Remuneration Information filings. The document length is 2250 characters, which is relatively short but contains substantive remuneration details rather than just an announcement of a report. Therefore, the appropriate classification is Remuneration Information (DEF 14A).
2023-03-30 Chinese
关于董事会提议向下修正可转换债券转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 健帆生物科技集团股份有限公司 regarding a proposal to downward adjust the conversion price of its convertible bonds. It details the bond issuance, listing, conversion period, previous adjustments to the conversion price, the conditions triggering the downward adjustment, and the procedure for approval by the shareholders' meeting. The document is a formal disclosure of a corporate action related to convertible bonds and capital structure, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the bond price adjustment proposal and related corporate governance matters. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond price adjustments.
2023-03-30 Chinese
中航证券有限公司关于公司2022年度定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度定期现场检查报告" which translates to "2022 Annual Regular On-site Inspection Report" by 中航证券有限公司 (China Aviation Securities Co., Ltd.) regarding 健帆生物科技集团股份有限公司 (Jianfan Biotechnology Group Co., Ltd.). The content details a comprehensive on-site inspection covering company governance, internal control, information disclosure, protection of company interests, use of raised funds, performance, shareholder commitments, and other important matters. It includes detailed checklists and compliance verification but does not contain financial statements or typical annual report content. The document length is 3476 characters, which is relatively short and focused on inspection findings rather than full financial reporting. This type of document is a regulatory or compliance inspection report rather than an annual report, audit report, or earnings release. It does not fit the definitions of other categories such as management changes, voting results, or capital updates. Given the nature of the document as a regulatory inspection report by a securities firm, the best fitting category is Audit Report / Information (AR), which includes results of internal or regulatory stress tests and audit-related reports excluding full annual reports. Confidence is high due to the clear labeling and content focus on inspection and compliance verification. FY 2022
2023-03-30 Chinese
2022年度独立董事述职报告（周凌宏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2022" for a company, detailing the independent director's attendance at board and shareholder meetings, committee participation, opinions on various board matters, on-site investigations, investor protection efforts, and training. It is a detailed report on the independent director's duties and activities during the year 2022. It is not an annual report, audit report, or earnings release. It is not a short announcement or a certification. The content focuses on board/management information, specifically the independent director's report on their role and activities, which fits best under Board/Management Information (MANG). The document length is 4169 characters, which is substantial for a report of this nature. Therefore, the classification is MANG with high confidence.
2023-03-30 Chinese
致同会计师事务所（特殊普通合伙）关于公司非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding non-operating fund occupation and other related party fund transactions for the year 2022 by 健帆生物科技集团股份有限公司. It includes a detailed summary table of these transactions and is addressed to an accounting firm. The document references an audit report issued by the accounting firm for the 2022 financial statements but is itself a specific supplementary disclosure related to regulatory requirements on fund occupation and related party transactions. It is not a full annual report, audit report, or financial statement but a specialized disclosure report. The document length is about 3,048 characters, which is relatively short but contains substantive data and explanations, not just an announcement or certification. This type of document fits best under Audit Report / Information (AR) as it relates to audit findings and regulatory compliance disclosures on specific financial matters, distinct from the full annual report or interim report. Therefore, the classification is AR with high confidence. FY 2022
2023-03-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.